Genmab shares fell on Monday after the company said it would end the development of blood-cancer treatment HexaBody-CD38 because Johnson & Johnson won't exercise its option to license it.

However, an enzyme called CD38 breaks down the NAD, causing it to leak from cells. This leak gets accelerated with age and causes issues of aging and low energy levels. This MitoThrive formula is ...

Copenhagen-based biotech firm Genmab A/S disclosed today that Johnson & Johnson will not advance the HexaBody-CD38 program, as detailed in a recent SEC filing. The announcement was made in a Form ...